BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Science in Boston - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Science in Boston
X-ORIGINAL-URL:https://scienceinboston.com
X-WR-CALDESC:Events for Science in Boston
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20180311T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20181104T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20190310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20191103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200204T170000
DTEND;TZID=America/New_York:20200204T203000
DTSTAMP:20260501T074518
CREATED:20200102T201953Z
LAST-MODIFIED:20200102T201953Z
UID:7672-1580835600-1580848200@scienceinboston.com
SUMMARY:Venture Funding Happy Hour at M2D2!
DESCRIPTION:Startups: If you’re committed to your business vision\, then you MUST start planning for venture financing. \nEven if your startup is brand-new\, NOW is the time to map out your complete business growth path — all the way to venture financing. \nThis happy hour event will bring your startup one step closer to your business goals. Get a crystal-clear picture of the process as we welcome four noted life science business financing experts to our Lowell center after work on Tuesday\, February 4th. \nJoin us and: \n\nUnderstand how venture financing works today.\nLearn what to look for (and look OUT for) in a VC offer.\nLearn how to prepare your full business financing plan—from angel investors to VCs.\nFind out the preparations you need to make to advance to each stage of financing.\nGet expert answers to all your business financing questions.\nNetwork with VCs\, other investors\, and your entrepreneur peers.\nEnjoy complimentary snacks and beverages.\n\nPLUS\, practice and improve your pitch! \nCome with your pitch deck\, because you can enter your name to give your business presentation and get valuable feedback from our panel. \nAgenda: \n5:00 – Registration & Networking w/ food & drink \n5:30 – Venture Capital Panel with Bill Yelle\, Nancy Briefs\, Maria Berkman\, and moderator Vinit Nijhawan. \n6:30 – Q&A and Networking \n  \n  \nOnline tickets: $10.00 \nWalk-ins: $20.00 \n*This event will also include a 200k Challenge 2020 Info Session* \n*Free parking included* \n  \n  \nMeet the Panel: \n  \n  \nVinit Nijhawan is Interim Executive Director at Massachusetts Technology Transfer Center in UMass President’s Office. Vinit was Managing Director at UnitedLex focused on academic IP commercialization. Vinit was Managing Director\, Office of Technology Development at Boston University where he launched 8 venture-backed spinoffs and successfully executed a patent monetization program. Vinit teaches MBA courses on Entrepreneurship at BU Questrom School of Business\, over 450 students have taken his courses. Vinit has over 30 years experience building five startups: as CEO of three\, five were acquired. Vinit was Venture Partner at Key Venture Partners and his one investment was acquired for $430M. Vinit is an advisor and board member to several technology startups and was a Mass High Tech All-Star in 2005. Vinit has participated in over 240 panel discussions and paper presentations\, and was a Board Member of Mass Ventures\, an early stage\, quasi-public Massachusetts venture capital firm\, a co-founder of EdTech Accelerator/Incubator LearnLaunch\, ex-President of Massachusetts Association of Technology Transfer Offices and co-founder of Waterloo Alumni Angels. Vinit is also serving or has served on non-profit boards of VentureCafe Foundation\, National Academy of Inventors\, TiE Global. Vinit earned a B.A.Sc in electrical engineering from the University of Waterloo in Ontario\, Canada. \n________________________________________________________________________________________________________________ \nNancy Briefs‘ background includes 35+ years in the medical device industry. She is a serial entrepreneur and has been an integral team member responsible for successfully developing and commercializing innovative paradigm-shifting technologies with six (6) prior MedTech startups. Having raised over $500M in capital and six successful liquidity events (including an IPO with Goldman) she has proven the ability to lead teams from concept thru commercialization and value creation. She has served on the Boards of: HealthHelm\, Digital Cognition Technologies\, InfoBionic\, MyndBlu\, CardiAQ Valve Technologies\, MDMA (Medical Device and Manufacturers Association)\, Apama Medical\, Direct Flow Medical\, Eleme Medical\, and Percardia. \nAn entrepreneur inventor she is listed on seven issued and two pending US patents. \nNancy has an MBA in Marketing and Finance from Golden Gate University and a BA and BSB from Emporia University. \n________________________________________________________________________________________________________________ \nWilliam E. Yelle \nEntrepreneur in Residence at Partners Innovation \nBill has spent over 30 years in the biopharmaceutical industry\, with experience ranging from large pharma to early stage\, venture-backed companies. He currently serves as Executive Chairman of Envisia Therapeutics\, as well as an advisor to several entrepreneurial startups. He is also an adjunct faculty member at the Manning School of Business. \nPrior to Envisia\, Bill served as CEO of Aldea Pharmaceuticals\, where he built an executive team\, completed a successful $28 M Series B raise and brought two programs into the clinic. Prior to Aldea\, he was Senior Vice President of Corporate Development and Licensing for Sunovion Pharmaceuticals Inc. (formerly Sepracor Inc.). While at Sepracor\, Bill was instrumental in the companies’ transition from an early stage clinical organization with just over 30 employees into a fully integrated pharmaceutical company consisting of close to 3\,000. At Sepracor\, he was responsible for the consummation of over 30 material transactions\, the most notable being the company’s sale to Dainippon Sumitomo Pharma for $2.6 billion in 2009. Prior to joining Sepracor in 1995\, Bill held various positions of increasing responsibility in Pfizer’s U.S\, Pharmaceuticals Group. \nIn addition to working as Executive Chair at Envisia\, Bill has served on the boards of LQ3 Pharma and Aldea Pharmaceuticals. \nBill has an M.B.A. in Management/Marketing from Columbia University\, a M.S. in Organic Chemistry from the University of California at Berkeley and a B.S. Cum Laude from the University of Massachusetts Lowell. \n______________________________________________________________________________________________________ \nMaria Berkman\, MD\, MBA\, \nDirector\, and Head of the MedTech practice\, Broadview Ventures. \nMaria shares responsibility for all aspects of Broadview’s investment activity\, from identification and screening of new opportunities\, through due diligence\, negotiation of deal structure\, and portfolio company board involvement. \nPrior to joining Broadview Ventures\, Maria was a management consultant at Monitor Group\, where she specialized in life sciences with a focus on corporate\, franchise\, and asset-level commercialization strategy and competitive strategic planning for both BioPharma and MedTech clients. Prior to joining Monitor Group\, Maria trained within the Partners HealthCare System at Newton Wellesley Hospital in General Surgery. Maria earned an MD from the UCLA School of Medicine\, graduating Alpha Omega Alpha with a research focus in cardiothoracic and trauma surgery\, and earned an MBA from the Anderson School of Management at UCLA. \nMaria serves on the boards of Adient\, Aria CV\, AtaCor\, FineHeart\, Vascular Graft Solutions and Vectorious\, and previously served on the boards of Apama (acquired by Boston Scientific) and Capricor (NASD:CAPR). \nIn addition to her role at Broadview Ventures\, Maria contributes time as a SBIR/STTR grant reviewer for the National Science Foundation and is a Strategic Advisory Board Member for the RAD BioMed Accelerator in Tel Aviv\, Israel.
URL:https://scienceinboston.com/event/venture-funding-happy-hour-at-m2d2/
LOCATION:M2D2\, 110 Canal Street\, 4th Floor\, Lowell\, MA\, 01854\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200204T170000
DTEND;TZID=America/New_York:20200204T203000
DTSTAMP:20260501T074518
CREATED:20200102T201953Z
LAST-MODIFIED:20200102T201953Z
UID:27426-1580835600-1580848200@scienceinboston.com
SUMMARY:Venture Funding Happy Hour at M2D2!
DESCRIPTION:Startups: If you’re committed to your business vision\, then you MUST start planning for venture financing. \nEven if your startup is brand-new\, NOW is the time to map out your complete business growth path — all the way to venture financing. \nThis happy hour event will bring your startup one step closer to your business goals. Get a crystal-clear picture of the process as we welcome four noted life science business financing experts to our Lowell center after work on Tuesday\, February 4th. \nJoin us and: \n\nUnderstand how venture financing works today.\nLearn what to look for (and look OUT for) in a VC offer.\nLearn how to prepare your full business financing plan—from angel investors to VCs.\nFind out the preparations you need to make to advance to each stage of financing.\nGet expert answers to all your business financing questions.\nNetwork with VCs\, other investors\, and your entrepreneur peers.\nEnjoy complimentary snacks and beverages.\n\nPLUS\, practice and improve your pitch! \nCome with your pitch deck\, because you can enter your name to give your business presentation and get valuable feedback from our panel. \nAgenda: \n5:00 – Registration & Networking w/ food & drink \n5:30 – Venture Capital Panel with Bill Yelle\, Nancy Briefs\, Maria Berkman\, and moderator Vinit Nijhawan. \n6:30 – Q&A and Networking \n  \n  \nOnline tickets: $10.00 \nWalk-ins: $20.00 \n*This event will also include a 200k Challenge 2020 Info Session* \n*Free parking included* \n  \n  \nMeet the Panel: \n  \n  \nVinit Nijhawan is Interim Executive Director at Massachusetts Technology Transfer Center in UMass President’s Office. Vinit was Managing Director at UnitedLex focused on academic IP commercialization. Vinit was Managing Director\, Office of Technology Development at Boston University where he launched 8 venture-backed spinoffs and successfully executed a patent monetization program. Vinit teaches MBA courses on Entrepreneurship at BU Questrom School of Business\, over 450 students have taken his courses. Vinit has over 30 years experience building five startups: as CEO of three\, five were acquired. Vinit was Venture Partner at Key Venture Partners and his one investment was acquired for $430M. Vinit is an advisor and board member to several technology startups and was a Mass High Tech All-Star in 2005. Vinit has participated in over 240 panel discussions and paper presentations\, and was a Board Member of Mass Ventures\, an early stage\, quasi-public Massachusetts venture capital firm\, a co-founder of EdTech Accelerator/Incubator LearnLaunch\, ex-President of Massachusetts Association of Technology Transfer Offices and co-founder of Waterloo Alumni Angels. Vinit is also serving or has served on non-profit boards of VentureCafe Foundation\, National Academy of Inventors\, TiE Global. Vinit earned a B.A.Sc in electrical engineering from the University of Waterloo in Ontario\, Canada. \n________________________________________________________________________________________________________________ \nNancy Briefs‘ background includes 35+ years in the medical device industry. She is a serial entrepreneur and has been an integral team member responsible for successfully developing and commercializing innovative paradigm-shifting technologies with six (6) prior MedTech startups. Having raised over $500M in capital and six successful liquidity events (including an IPO with Goldman) she has proven the ability to lead teams from concept thru commercialization and value creation. She has served on the Boards of: HealthHelm\, Digital Cognition Technologies\, InfoBionic\, MyndBlu\, CardiAQ Valve Technologies\, MDMA (Medical Device and Manufacturers Association)\, Apama Medical\, Direct Flow Medical\, Eleme Medical\, and Percardia. \nAn entrepreneur inventor she is listed on seven issued and two pending US patents. \nNancy has an MBA in Marketing and Finance from Golden Gate University and a BA and BSB from Emporia University. \n________________________________________________________________________________________________________________ \nWilliam E. Yelle \nEntrepreneur in Residence at Partners Innovation \nBill has spent over 30 years in the biopharmaceutical industry\, with experience ranging from large pharma to early stage\, venture-backed companies. He currently serves as Executive Chairman of Envisia Therapeutics\, as well as an advisor to several entrepreneurial startups. He is also an adjunct faculty member at the Manning School of Business. \nPrior to Envisia\, Bill served as CEO of Aldea Pharmaceuticals\, where he built an executive team\, completed a successful $28 M Series B raise and brought two programs into the clinic. Prior to Aldea\, he was Senior Vice President of Corporate Development and Licensing for Sunovion Pharmaceuticals Inc. (formerly Sepracor Inc.). While at Sepracor\, Bill was instrumental in the companies’ transition from an early stage clinical organization with just over 30 employees into a fully integrated pharmaceutical company consisting of close to 3\,000. At Sepracor\, he was responsible for the consummation of over 30 material transactions\, the most notable being the company’s sale to Dainippon Sumitomo Pharma for $2.6 billion in 2009. Prior to joining Sepracor in 1995\, Bill held various positions of increasing responsibility in Pfizer’s U.S\, Pharmaceuticals Group. \nIn addition to working as Executive Chair at Envisia\, Bill has served on the boards of LQ3 Pharma and Aldea Pharmaceuticals. \nBill has an M.B.A. in Management/Marketing from Columbia University\, a M.S. in Organic Chemistry from the University of California at Berkeley and a B.S. Cum Laude from the University of Massachusetts Lowell. \n______________________________________________________________________________________________________ \nMaria Berkman\, MD\, MBA\, \nDirector\, and Head of the MedTech practice\, Broadview Ventures. \nMaria shares responsibility for all aspects of Broadview’s investment activity\, from identification and screening of new opportunities\, through due diligence\, negotiation of deal structure\, and portfolio company board involvement. \nPrior to joining Broadview Ventures\, Maria was a management consultant at Monitor Group\, where she specialized in life sciences with a focus on corporate\, franchise\, and asset-level commercialization strategy and competitive strategic planning for both BioPharma and MedTech clients. Prior to joining Monitor Group\, Maria trained within the Partners HealthCare System at Newton Wellesley Hospital in General Surgery. Maria earned an MD from the UCLA School of Medicine\, graduating Alpha Omega Alpha with a research focus in cardiothoracic and trauma surgery\, and earned an MBA from the Anderson School of Management at UCLA. \nMaria serves on the boards of Adient\, Aria CV\, AtaCor\, FineHeart\, Vascular Graft Solutions and Vectorious\, and previously served on the boards of Apama (acquired by Boston Scientific) and Capricor (NASD:CAPR). \nIn addition to her role at Broadview Ventures\, Maria contributes time as a SBIR/STTR grant reviewer for the National Science Foundation and is a Strategic Advisory Board Member for the RAD BioMed Accelerator in Tel Aviv\, Israel.
URL:https://scienceinboston.com/event/venture-funding-happy-hour-at-m2d2-2/
LOCATION:M2D2\, 110 Canal Street\, 4th Floor\, Lowell\, MA\, 01854\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200130T170000
DTEND;TZID=America/New_York:20200130T190000
DTSTAMP:20260501T074518
CREATED:20200102T191715Z
LAST-MODIFIED:20200102T191715Z
UID:7665-1580403600-1580410800@scienceinboston.com
SUMMARY:MassBio Young Professionals Event: Trivia Night
DESCRIPTION:Join MassBio and FUJIFILM for Trivia Night! Rounds will cover: music\, movies\, TV\, science\, technology\, history\, literature\, Star Wars\, Harry Potter\, etc. Grab a drink and show off your smarts\, all while networking. Space is limited. Drinks and appetizers will be provided. MassBio Members only. This event is being held at FUJIFILM: One Kendall Square\, Binney St. Building 400\, First Floor\, Cambridge\, MA.
URL:https://scienceinboston.com/event/massbio-young-professionals-event-trivia-night/
LOCATION:FUJIFILM\, One Kendall Square\, Binney St. Building 400\, First Floor\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200130T170000
DTEND;TZID=America/New_York:20200130T190000
DTSTAMP:20260501T074518
CREATED:20200102T191715Z
LAST-MODIFIED:20200102T191715Z
UID:27424-1580403600-1580410800@scienceinboston.com
SUMMARY:MassBio Young Professionals Event: Trivia Night
DESCRIPTION:Join MassBio and FUJIFILM for Trivia Night! Rounds will cover: music\, movies\, TV\, science\, technology\, history\, literature\, Star Wars\, Harry Potter\, etc. Grab a drink and show off your smarts\, all while networking. Space is limited. Drinks and appetizers will be provided. MassBio Members only. This event is being held at FUJIFILM: One Kendall Square\, Binney St. Building 400\, First Floor\, Cambridge\, MA.
URL:https://scienceinboston.com/event/massbio-young-professionals-event-trivia-night-2/
LOCATION:FUJIFILM\, One Kendall Square\, Binney St. Building 400\, First Floor\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200128T150000
DTEND;TZID=America/New_York:20200128T170000
DTSTAMP:20260501T074518
CREATED:20200102T191348Z
LAST-MODIFIED:20200102T191348Z
UID:7662-1580223600-1580230800@scienceinboston.com
SUMMARY:First Annual “Patient Safety in a Digital World” Symposium
DESCRIPTION:The Foundation for the Innovation and Development of Health Safety (FIDHS) is pleased to convene our 1st Annual International Patient Safety Symposium at Dana-Farber Cancer Institute in Boston. In an effort to move the needle on patient safety\, the symposium will convene thought leaders in digital health innovation\, hospital CEOs and their pharmacy leaders\, and patient safety executives from across the U.S. and Europe to address the latest digital strategies that ensure patient safety for hospitals\, insurers\, and pharma manufacturers. The symposium provides a global platform for medical professionals and innovators to collaborate on a vision of patient safety in a digital world\, providing insights and recommendations based on real world digital programs. \nMassBio President & CEO Robert K. Coughlin will deliver the Closing Keynote. Register to attend the event. \nAgenda Outline \n\n\n3:00 – 3:15 PM Welcome/Refreshments \n3:15 – 3:30 PM Opening Remarks \n3:30 – 4:15 PM Executive Panel Discussion: “Patient Safety\, International Considerations & Lessons Learned” \n4:15 – 4:45 PM Special Guest Speaker \n4:45 – 5:30 PM Executive Panel Discussion: “Safety in a Digital World\, Opportunities for Disruption” \n5:30 – 6:00 PM Closing Remarks \n6:00 – 8:00 PM Cocktail/Networking Reception
URL:https://scienceinboston.com/event/first-annual-patient-safety-in-a-digital-world-symposium/
LOCATION:Dana Farber Cancer Institute\, 450 Brookline Avenue\, Yawkey Center for Cancer Care\, Lavine Family Dining Pavilion\, 3rd Floor\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200128T150000
DTEND;TZID=America/New_York:20200128T170000
DTSTAMP:20260501T074518
CREATED:20200102T191348Z
LAST-MODIFIED:20200102T191348Z
UID:27423-1580223600-1580230800@scienceinboston.com
SUMMARY:First Annual “Patient Safety in a Digital World” Symposium
DESCRIPTION:The Foundation for the Innovation and Development of Health Safety (FIDHS) is pleased to convene our 1st Annual International Patient Safety Symposium at Dana-Farber Cancer Institute in Boston. In an effort to move the needle on patient safety\, the symposium will convene thought leaders in digital health innovation\, hospital CEOs and their pharmacy leaders\, and patient safety executives from across the U.S. and Europe to address the latest digital strategies that ensure patient safety for hospitals\, insurers\, and pharma manufacturers. The symposium provides a global platform for medical professionals and innovators to collaborate on a vision of patient safety in a digital world\, providing insights and recommendations based on real world digital programs. \nMassBio President & CEO Robert K. Coughlin will deliver the Closing Keynote. Register to attend the event. \nAgenda Outline \n\n\n3:00 – 3:15 PM Welcome/Refreshments \n3:15 – 3:30 PM Opening Remarks \n3:30 – 4:15 PM Executive Panel Discussion: “Patient Safety\, International Considerations & Lessons Learned” \n4:15 – 4:45 PM Special Guest Speaker \n4:45 – 5:30 PM Executive Panel Discussion: “Safety in a Digital World\, Opportunities for Disruption” \n5:30 – 6:00 PM Closing Remarks \n6:00 – 8:00 PM Cocktail/Networking Reception
URL:https://scienceinboston.com/event/first-annual-patient-safety-in-a-digital-world-symposium-2/
LOCATION:Dana Farber Cancer Institute\, 450 Brookline Avenue\, Yawkey Center for Cancer Care\, Lavine Family Dining Pavilion\, 3rd Floor\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200126T080000
DTEND;TZID=America/New_York:20200207T170000
DTSTAMP:20260501T074518
CREATED:20191209T231811Z
LAST-MODIFIED:20191209T231811Z
UID:7529-1580025600-1581094800@scienceinboston.com
SUMMARY:Program for Chairs of Clinical Services
DESCRIPTION:Overview\n\nChairs of major clinical departments traditionally have faced complex responsibilities because of their multiple tasks – patient care\, teaching\, research\, and administration. \nAs a result of the effects of health reform\, financial pressures\, and resource constraints\, many chairs are being asked by their institutions to become more extensively involved in institutional decision-making with regard to programs\, staffing\, operating and capital budgets\, and other issues\, such as the restructuring of the clinical enterprise. These responsibilities are in addition to their traditional concerns within their own departments. At the same time\, chairs have to consider to a greater degree the relationship between institutional priorities\, departmental decisions\, and collaboration with other services. These new tasks call for new leadership and managerial skills. \nThe Program for Chairs of Clinical Services brings together chairs of major clinical departments in teaching hospitals and health systems and an experienced interdisciplinary faculty for two weeks of intensive and systematic study of some of the critical leadership and management issues facing chairs\, their departments\, and teaching hospitals. \nCurriculum \nThe curriculum of the program is organized around the following interrelated courses taught by a faculty experienced in executive education for physicians and other key decision-makers in the health system: \n\nInstitutional Strategy\nHealth Policy\nFinancial Analysis and Control\nOperations Management\nOrganizational Issues\nLeadership Challenges\n\nA carefully integrated curriculum permits participants to examine fundamental managerial issues from the perspective of several disciplines. A new program initiative or downsizing proposal\, for example\, may raise managerial problems concerning departmental and institutional strategy; the application and utility of systems analysis and quantitative analytical methods; basic economic trends and legal constraints; financial analysis and control; and organizational behavior\, design\, and development. \nThe overriding purpose for learning concepts\, techniques\, and skills in any of the management disciplines in this program is to understand their managerial use and limitations. For example\, the course in financial analysis and control does not aim to develop expert accountants or to provide accounting skills\, per se. The purpose in learning to analyze the cost and financial implications of program decisions\, for instance\, is: (a) to better understand the fundamental methodological issues involved\, the driving factors behind any particular analysis\, the limits of such analysis\, and the need to blend this with clinical\, strategic\, and other non-financial judgements; and (b) to improve the ability of a participant both to manage staff and to interact more effectively with the fiscal affairs personnel in their hospital\, health system\, or medical school. \nTeaching Method \nThe principal method of instruction in the program is the case method\, a technique pioneered and refined at Harvard Business School. Most of the cases present actual problem situations familiar to chairs of clinical departments. Special case materials based on field studies of specific issues faced by service chairs have been and continue to be prepared by the faculty. \nThe case method confronts the participant with an actual management problem\, halted at a point where decisions must be made\, and forces the participant to choose a course of action. Participants go through a three-step study process. First\, participants study each case independently. Participants then meet in small discussion groups to test their individual analyses against those of their peers. Finally\, the entire class discusses the case\, with the professor as catalyst and guide. The professor points out considerations the class has overlooked; elicits from participants the lessons of experience; pursues each line of investigation to its conclusion; and finally\, summarizes the discussion and draws out the major lessons it has taught. \nAssigned readings and guest lecturers supplement and augment the use of cases. In addition\, an important part of the learning process occurs during the informal exchange of insights and experience among participants and faculty. \nProgram Organization \nClasses and discussion groups are scheduled six days a week. Preparation for classes averages six hours a day. Registration is scheduled for 3:00 – 4:00 pm on the opening Sunday of the program. The following Sunday is free except for cases to be prepared for Monday’s classes. The program concludes on the second Friday at 2:00 pm. Participants are required to free themselves of professional and family responsibilities for the period of the program so that full attention can be devoted to the educational experience.
URL:https://scienceinboston.com/event/program-for-chairs-of-clinical-services/
LOCATION:Harvard Longwood Campus\, Boston\, MA\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200126T080000
DTEND;TZID=America/New_York:20200207T170000
DTSTAMP:20260501T074518
CREATED:20191209T231811Z
LAST-MODIFIED:20191209T231811Z
UID:27420-1580025600-1581094800@scienceinboston.com
SUMMARY:Program for Chairs of Clinical Services
DESCRIPTION:Overview\n\nChairs of major clinical departments traditionally have faced complex responsibilities because of their multiple tasks – patient care\, teaching\, research\, and administration. \nAs a result of the effects of health reform\, financial pressures\, and resource constraints\, many chairs are being asked by their institutions to become more extensively involved in institutional decision-making with regard to programs\, staffing\, operating and capital budgets\, and other issues\, such as the restructuring of the clinical enterprise. These responsibilities are in addition to their traditional concerns within their own departments. At the same time\, chairs have to consider to a greater degree the relationship between institutional priorities\, departmental decisions\, and collaboration with other services. These new tasks call for new leadership and managerial skills. \nThe Program for Chairs of Clinical Services brings together chairs of major clinical departments in teaching hospitals and health systems and an experienced interdisciplinary faculty for two weeks of intensive and systematic study of some of the critical leadership and management issues facing chairs\, their departments\, and teaching hospitals. \nCurriculum \nThe curriculum of the program is organized around the following interrelated courses taught by a faculty experienced in executive education for physicians and other key decision-makers in the health system: \n\nInstitutional Strategy\nHealth Policy\nFinancial Analysis and Control\nOperations Management\nOrganizational Issues\nLeadership Challenges\n\nA carefully integrated curriculum permits participants to examine fundamental managerial issues from the perspective of several disciplines. A new program initiative or downsizing proposal\, for example\, may raise managerial problems concerning departmental and institutional strategy; the application and utility of systems analysis and quantitative analytical methods; basic economic trends and legal constraints; financial analysis and control; and organizational behavior\, design\, and development. \nThe overriding purpose for learning concepts\, techniques\, and skills in any of the management disciplines in this program is to understand their managerial use and limitations. For example\, the course in financial analysis and control does not aim to develop expert accountants or to provide accounting skills\, per se. The purpose in learning to analyze the cost and financial implications of program decisions\, for instance\, is: (a) to better understand the fundamental methodological issues involved\, the driving factors behind any particular analysis\, the limits of such analysis\, and the need to blend this with clinical\, strategic\, and other non-financial judgements; and (b) to improve the ability of a participant both to manage staff and to interact more effectively with the fiscal affairs personnel in their hospital\, health system\, or medical school. \nTeaching Method \nThe principal method of instruction in the program is the case method\, a technique pioneered and refined at Harvard Business School. Most of the cases present actual problem situations familiar to chairs of clinical departments. Special case materials based on field studies of specific issues faced by service chairs have been and continue to be prepared by the faculty. \nThe case method confronts the participant with an actual management problem\, halted at a point where decisions must be made\, and forces the participant to choose a course of action. Participants go through a three-step study process. First\, participants study each case independently. Participants then meet in small discussion groups to test their individual analyses against those of their peers. Finally\, the entire class discusses the case\, with the professor as catalyst and guide. The professor points out considerations the class has overlooked; elicits from participants the lessons of experience; pursues each line of investigation to its conclusion; and finally\, summarizes the discussion and draws out the major lessons it has taught. \nAssigned readings and guest lecturers supplement and augment the use of cases. In addition\, an important part of the learning process occurs during the informal exchange of insights and experience among participants and faculty. \nProgram Organization \nClasses and discussion groups are scheduled six days a week. Preparation for classes averages six hours a day. Registration is scheduled for 3:00 – 4:00 pm on the opening Sunday of the program. The following Sunday is free except for cases to be prepared for Monday’s classes. The program concludes on the second Friday at 2:00 pm. Participants are required to free themselves of professional and family responsibilities for the period of the program so that full attention can be devoted to the educational experience.
URL:https://scienceinboston.com/event/program-for-chairs-of-clinical-services-2/
LOCATION:Harvard Longwood Campus\, Boston\, MA\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200124T090000
DTEND;TZID=America/New_York:20200124T113000
DTSTAMP:20260501T074518
CREATED:20200102T191157Z
LAST-MODIFIED:20200102T191157Z
UID:7659-1579856400-1579865400@scienceinboston.com
SUMMARY:Don't Screw It Up - Choosing The Right Consultant: Important Considerations in Selecting the Right Regulatory and Quality Consultants for Your Projects
DESCRIPTION:Larger pharma company regulatory affairs and quality departments are constantly being asked to do more with no increase in resources. Smaller companies and foreign companies often do not have any or enough US based staff or staff with the appropriate expertise to meet their business goals. Thus the use of consultants to provide assistance is a significant and growing trend in both the pharmaceutical and medical device industries. \nBut how does one go about choosing a consultant group? Use a big CRO-type organization? Contact a single proprietor? Are there alternatives to consider in terms of therapeutic area\, geography\, on-site or remote work\, other potential add–on services that are offered\, etc.? This session will present the perspectives and learnings of a senior regulatory affairs executive with decades of successful experience and who has worked in both pharma and the consultancy industries. Similarly\, the second presenter will be a long-standing quality and compliance professional. \nIn choosing and utilizing regulatory and quality consultants for both tactical and strategic activities there are many attributes to consider. What information should you provide to allow a consultant to appropriately scope out\, determine timelines and resources\, and price a project? How should one compare proposals from different consultants? What should you verify with a consultant before signing the contract? An experienced consultancy executive will provide these insights and advise participants on what is needed to make the relationship work smoothly so that your objectives are fully realized. \nUse of regulatory affairs and quality consultants in the device/pharma industry is projected to continue to increase by 10% or more annually. Intermediate and senior level attendees will be able to apply the information shared during the presentations and Q&A session in their normal work activities as they consider adding consultants to complete business objectives. \nLearning Objectives: \n• Describe the key considerations in choosing an appropriate regulatory and quality consultant to meet business objectives. \n• Explain to a potential regulatory or quality consultant the essential aspects of a project that will allow an achievable timeline\, service delivery\, and budget to be presented for consideration. \nYour presenters will be Andrew S. Verderame\, Partner\, PharmaLex US Corporation and Gerardo Gomez\, Sr. Director Quality & Compliance\, PharmaLex US Corporation. \nA light breakfast will be served and there will be plenty of time for Q & A at the conclusion of the presentation.
URL:https://scienceinboston.com/event/dont-screw-it-up-choosing-the-right-consultant-important-considerations-in-selecting-the-right-regulatory-and-quality-consultants-for-your-projects/
LOCATION:MassBio\, 300 Technology Square 8th Fl\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200124T090000
DTEND;TZID=America/New_York:20200124T113000
DTSTAMP:20260501T074518
CREATED:20200102T191157Z
LAST-MODIFIED:20200102T191157Z
UID:27422-1579856400-1579865400@scienceinboston.com
SUMMARY:Don't Screw It Up - Choosing The Right Consultant: Important Considerations in Selecting the Right Regulatory and Quality Consultants for Your Projects
DESCRIPTION:Larger pharma company regulatory affairs and quality departments are constantly being asked to do more with no increase in resources. Smaller companies and foreign companies often do not have any or enough US based staff or staff with the appropriate expertise to meet their business goals. Thus the use of consultants to provide assistance is a significant and growing trend in both the pharmaceutical and medical device industries. \nBut how does one go about choosing a consultant group? Use a big CRO-type organization? Contact a single proprietor? Are there alternatives to consider in terms of therapeutic area\, geography\, on-site or remote work\, other potential add–on services that are offered\, etc.? This session will present the perspectives and learnings of a senior regulatory affairs executive with decades of successful experience and who has worked in both pharma and the consultancy industries. Similarly\, the second presenter will be a long-standing quality and compliance professional. \nIn choosing and utilizing regulatory and quality consultants for both tactical and strategic activities there are many attributes to consider. What information should you provide to allow a consultant to appropriately scope out\, determine timelines and resources\, and price a project? How should one compare proposals from different consultants? What should you verify with a consultant before signing the contract? An experienced consultancy executive will provide these insights and advise participants on what is needed to make the relationship work smoothly so that your objectives are fully realized. \nUse of regulatory affairs and quality consultants in the device/pharma industry is projected to continue to increase by 10% or more annually. Intermediate and senior level attendees will be able to apply the information shared during the presentations and Q&A session in their normal work activities as they consider adding consultants to complete business objectives. \nLearning Objectives: \n• Describe the key considerations in choosing an appropriate regulatory and quality consultant to meet business objectives. \n• Explain to a potential regulatory or quality consultant the essential aspects of a project that will allow an achievable timeline\, service delivery\, and budget to be presented for consideration. \nYour presenters will be Andrew S. Verderame\, Partner\, PharmaLex US Corporation and Gerardo Gomez\, Sr. Director Quality & Compliance\, PharmaLex US Corporation. \nA light breakfast will be served and there will be plenty of time for Q & A at the conclusion of the presentation.
URL:https://scienceinboston.com/event/dont-screw-it-up-choosing-the-right-consultant-important-considerations-in-selecting-the-right-regulatory-and-quality-consultants-for-your-projects-2/
LOCATION:MassBio\, 300 Technology Square 8th Fl\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200122T180000
DTEND;TZID=America/New_York:20200122T210000
DTSTAMP:20260501T074518
CREATED:20200102T190923Z
LAST-MODIFIED:20200102T190923Z
UID:7657-1579716000-1579726800@scienceinboston.com
SUMMARY:Going Beyond the Gut: The Future of Microbiome Therapeutics
DESCRIPTION:The microbiome market is one of the hottest areas for innovation in the life sciences space.  We are seeing an uptick in both research and venture capital dollars going into the microbiome industry—both in humans and plants.  As a result\, the global microbiome market is expected to grow from $235.8 million in 2018 to $521.23 million by 2022. \nPlease join us for a panel discussion led by some of Boston’s most innovative companies in the space to learn about the science behind the microbiome\, the utilization of emerging technologies\, and various perspectives on the future of the industry. \nConfirmed Speakers \nRyan Barrett\, VP\, Corporate Development & IP\,  Axial Biotherapeutics \nDr. Martha Herbert \, Assistant Professor of Neurology\, Harvard Medical School\, Pediatric Neurologist and Neuroscientist\,  Massachusetts General Hospital \nGeoff van Maltzahn\, Co-founder and Chief Innovation Officer\,  Indigo \n 
URL:https://scienceinboston.com/event/going-beyond-the-gut-the-future-of-microbiome-therapeutics-2/
LOCATION:Broad Institute of MIT and Harvard\, 415 Main Street Auditorium\, Cambridge\, MA\, 02142\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200122T180000
DTEND;TZID=America/New_York:20200122T210000
DTSTAMP:20260501T074518
CREATED:20200102T190923Z
LAST-MODIFIED:20200102T190923Z
UID:27421-1579716000-1579726800@scienceinboston.com
SUMMARY:Going Beyond the Gut: The Future of Microbiome Therapeutics
DESCRIPTION:The microbiome market is one of the hottest areas for innovation in the life sciences space.  We are seeing an uptick in both research and venture capital dollars going into the microbiome industry—both in humans and plants.  As a result\, the global microbiome market is expected to grow from $235.8 million in 2018 to $521.23 million by 2022. \nPlease join us for a panel discussion led by some of Boston’s most innovative companies in the space to learn about the science behind the microbiome\, the utilization of emerging technologies\, and various perspectives on the future of the industry. \nConfirmed Speakers \nRyan Barrett\, VP\, Corporate Development & IP\,  Axial Biotherapeutics \nDr. Martha Herbert \, Assistant Professor of Neurology\, Harvard Medical School\, Pediatric Neurologist and Neuroscientist\,  Massachusetts General Hospital \nGeoff van Maltzahn\, Co-founder and Chief Innovation Officer\,  Indigo \n 
URL:https://scienceinboston.com/event/going-beyond-the-gut-the-future-of-microbiome-therapeutics-2-2/
LOCATION:Broad Institute of MIT and Harvard\, 415 Main Street Auditorium\, Cambridge\, MA\, 02142\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200122T160000
DTEND;TZID=America/New_York:20200122T180000
DTSTAMP:20260501T074518
CREATED:20191209T231059Z
LAST-MODIFIED:20191209T231059Z
UID:7521-1579708800-1579716000@scienceinboston.com
SUMMARY:38th Annual JP Morgan Healthcare Conference Recap & 2020 Outlook
DESCRIPTION:The annual JP Morgan Healthcare Conference in San Francisco is one of the largest and most informative healthcare investment symposiums in the industry. It brings together global industry leaders\, emerging fast-growth companies\, innovative technology creators and members of the investment community. Each year hundreds of companies\, both public and private\, deliver presentations to over 4\,000 investors. In addition\, thousands in biotech descend upon San Francisco to network\, attend meetings and gain an inside view even if they can’t secure an official conference invite. If you can’t make it to the conference\, or if your role does not require you to attend the JP Morgan conference\, join us for a recap of it and hear ideas about the deals landscape for 2020 from a select group of conference insiders.
URL:https://scienceinboston.com/event/38th-annual-jp-morgan-healthcare-conference-recap-2020-outlook/
LOCATION:MassBio\, 300 Technology Square 8th Fl\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200122T160000
DTEND;TZID=America/New_York:20200122T180000
DTSTAMP:20260501T074518
CREATED:20191209T231059Z
LAST-MODIFIED:20191209T231059Z
UID:27418-1579708800-1579716000@scienceinboston.com
SUMMARY:38th Annual JP Morgan Healthcare Conference Recap & 2020 Outlook
DESCRIPTION:The annual JP Morgan Healthcare Conference in San Francisco is one of the largest and most informative healthcare investment symposiums in the industry. It brings together global industry leaders\, emerging fast-growth companies\, innovative technology creators and members of the investment community. Each year hundreds of companies\, both public and private\, deliver presentations to over 4\,000 investors. In addition\, thousands in biotech descend upon San Francisco to network\, attend meetings and gain an inside view even if they can’t secure an official conference invite. If you can’t make it to the conference\, or if your role does not require you to attend the JP Morgan conference\, join us for a recap of it and hear ideas about the deals landscape for 2020 from a select group of conference insiders.
URL:https://scienceinboston.com/event/38th-annual-jp-morgan-healthcare-conference-recap-2020-outlook-2/
LOCATION:MassBio\, 300 Technology Square 8th Fl\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200122T123000
DTEND;TZID=America/New_York:20200122T130000
DTSTAMP:20260501T074518
CREATED:20191209T230217Z
LAST-MODIFIED:20191209T230217Z
UID:7519-1579696200-1579698000@scienceinboston.com
SUMMARY:Synthetic Control Arms in Clinical Trials and Regulatory Applications
DESCRIPTION:Overview\n\nAs an increasing number of rare diseases and disease subsets become tractable to novel therapies\, there is growing pressure to increase the efficiency and effectiveness of clinical trials. One such approach is the use of real-world evidence\, such as synthetic control arms. Instead of recruiting patients who have been assigned to the control arm\, a synthetic control arm can repurpose historical clinical trial or real-world data to accurately match patients. This methodology has far-ranging applications in trial design\, replacement/augmentation of control groups and identifying differentiation in treatment effects across subpopulations. \nThis webinar will discuss the methodology and applicability of synthetic control arms\, especially those utilizing large clinical trial datasets\, in biopharma R&D. We will also discuss examples where synthetic controls have successfully been used in FDA applications\, and the emerging regulatory framework.
URL:https://scienceinboston.com/event/synthetic-control-arms-in-clinical-trials-and-regulatory-applications/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200122T123000
DTEND;TZID=America/New_York:20200122T130000
DTSTAMP:20260501T074518
CREATED:20191209T230217Z
LAST-MODIFIED:20191209T230217Z
UID:27417-1579696200-1579698000@scienceinboston.com
SUMMARY:Synthetic Control Arms in Clinical Trials and Regulatory Applications
DESCRIPTION:Overview\n\nAs an increasing number of rare diseases and disease subsets become tractable to novel therapies\, there is growing pressure to increase the efficiency and effectiveness of clinical trials. One such approach is the use of real-world evidence\, such as synthetic control arms. Instead of recruiting patients who have been assigned to the control arm\, a synthetic control arm can repurpose historical clinical trial or real-world data to accurately match patients. This methodology has far-ranging applications in trial design\, replacement/augmentation of control groups and identifying differentiation in treatment effects across subpopulations. \nThis webinar will discuss the methodology and applicability of synthetic control arms\, especially those utilizing large clinical trial datasets\, in biopharma R&D. We will also discuss examples where synthetic controls have successfully been used in FDA applications\, and the emerging regulatory framework.
URL:https://scienceinboston.com/event/synthetic-control-arms-in-clinical-trials-and-regulatory-applications-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200121T180000
DTEND;TZID=America/New_York:20200121T210000
DTSTAMP:20260501T074518
CREATED:20200102T192332Z
LAST-MODIFIED:20200102T192332Z
UID:7668-1579629600-1579640400@scienceinboston.com
SUMMARY:Seed and Angel Financing for Life Science Companies – Boston
DESCRIPTION:Life sciences entrepreneurs derive from a wide variety of geographic and educational backgrounds.  Young or old(er)\, most share a strong passion for translating their ideas and data into commercial products and services to benefit human health. While the work is rewarding\, it is a tremendously challenging endeavor\, from building the team to meeting regulatory requirements. Often\, the most daunting challenge is raising the financing needed to get started. The panelists for tonight’s ENET event have deep experience in launching life science startups\, from the perspectives of founder and investor\, and they are looking forward to sharing their insights with you. Please join us for an engaging discussion and stellar networking. \nAgenda: \n6:00-7:00 PM – Registration & Networking \n7:00-7:10 PM – ENET Chairman’s Announcements \n7:10-7:25 PM – eMinute PITCH – up to 3 startups give a 90-second elevator pitch \n7:25-8:15 PM – Expert speakers on the night’s topic \n8:15-8:30 PM – Q & A \n8:30-9:00 PM – Final networking\, including meeting speakers
URL:https://scienceinboston.com/event/seed-and-angel-financing-for-life-science-companies-boston/
LOCATION:Draper\, Hill Building\, One Hampshire St.\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200121T180000
DTEND;TZID=America/New_York:20200121T210000
DTSTAMP:20260501T074518
CREATED:20200102T192332Z
LAST-MODIFIED:20200102T192332Z
UID:27425-1579629600-1579640400@scienceinboston.com
SUMMARY:Seed and Angel Financing for Life Science Companies – Boston
DESCRIPTION:Life sciences entrepreneurs derive from a wide variety of geographic and educational backgrounds.  Young or old(er)\, most share a strong passion for translating their ideas and data into commercial products and services to benefit human health. While the work is rewarding\, it is a tremendously challenging endeavor\, from building the team to meeting regulatory requirements. Often\, the most daunting challenge is raising the financing needed to get started. The panelists for tonight’s ENET event have deep experience in launching life science startups\, from the perspectives of founder and investor\, and they are looking forward to sharing their insights with you. Please join us for an engaging discussion and stellar networking. \nAgenda: \n6:00-7:00 PM – Registration & Networking \n7:00-7:10 PM – ENET Chairman’s Announcements \n7:10-7:25 PM – eMinute PITCH – up to 3 startups give a 90-second elevator pitch \n7:25-8:15 PM – Expert speakers on the night’s topic \n8:15-8:30 PM – Q & A \n8:30-9:00 PM – Final networking\, including meeting speakers
URL:https://scienceinboston.com/event/seed-and-angel-financing-for-life-science-companies-boston-2/
LOCATION:Draper\, Hill Building\, One Hampshire St.\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200115T080000
DTEND;TZID=America/New_York:20200117T170000
DTSTAMP:20260501T074518
CREATED:20191209T225851Z
LAST-MODIFIED:20191209T225851Z
UID:7516-1579075200-1579280400@scienceinboston.com
SUMMARY:Recombinant Antibody and Biosimilars Course
DESCRIPTION:Overview\n\nRecombinant Antibody and Biosimilars course \nDates: January 15-17\, 2020 \nLocation: \nBiopharmaceutical Analysis Training Laboratory \nNortheastern University’s Innovation Campus \n147 S. Bedford Street\, Burlington\, MA 01803 \n  \nTOPICS COVERED \n\nGlycan analysis of immunoglobulins\nN- and C-terminal variants of antibody drugs\nStudy of disulfide connectivity and monitoring disulfide exchange\nMS based analysis of PK and metabolism of multivalent antibody drugs\nAnalysis of biosimilars in terms of variants and degradation products\n\n  \nLab course will be based on 1D gel and HPLC separation and LC/MS analysis of the following samples: \n\nIntact proteins\nReduced proteins e.g heavy and light chains\nTryptic digests which will contain glyco as well as other peptides\nGlycan mixtures released by glycosidase digestion of either the glycoprotein or enzyme digest\n\n  \nCost for this 2.5 training: \n$1900 per person\, Industry and Government \n$700 per person\, Academia \n  \nFor inquiries and to register\, email us at BATL@northeastern.edu \nFor more information about Northeastern’s Biopharmaceutical Analysis Training Laboratory\, visit our website: \nhttps://www.northeastern.edu/batl
URL:https://scienceinboston.com/event/recombinant-antibody-and-biosimilars-course/
LOCATION:Biopharmaceutical Analysis Training Laboratory\, Northeastern University’s Innovation Campus\, 147 S. Bedford Street\, Burlington\, MA\, 01803\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200115T080000
DTEND;TZID=America/New_York:20200117T170000
DTSTAMP:20260501T074518
CREATED:20191209T225851Z
LAST-MODIFIED:20191209T225851Z
UID:27416-1579075200-1579280400@scienceinboston.com
SUMMARY:Recombinant Antibody and Biosimilars Course
DESCRIPTION:Overview\n\nRecombinant Antibody and Biosimilars course \nDates: January 15-17\, 2020 \nLocation: \nBiopharmaceutical Analysis Training Laboratory \nNortheastern University’s Innovation Campus \n147 S. Bedford Street\, Burlington\, MA 01803 \n  \nTOPICS COVERED \n\nGlycan analysis of immunoglobulins\nN- and C-terminal variants of antibody drugs\nStudy of disulfide connectivity and monitoring disulfide exchange\nMS based analysis of PK and metabolism of multivalent antibody drugs\nAnalysis of biosimilars in terms of variants and degradation products\n\n  \nLab course will be based on 1D gel and HPLC separation and LC/MS analysis of the following samples: \n\nIntact proteins\nReduced proteins e.g heavy and light chains\nTryptic digests which will contain glyco as well as other peptides\nGlycan mixtures released by glycosidase digestion of either the glycoprotein or enzyme digest\n\n  \nCost for this 2.5 training: \n$1900 per person\, Industry and Government \n$700 per person\, Academia \n  \nFor inquiries and to register\, email us at BATL@northeastern.edu \nFor more information about Northeastern’s Biopharmaceutical Analysis Training Laboratory\, visit our website: \nhttps://www.northeastern.edu/batl
URL:https://scienceinboston.com/event/recombinant-antibody-and-biosimilars-course-2/
LOCATION:Biopharmaceutical Analysis Training Laboratory\, Northeastern University’s Innovation Campus\, 147 S. Bedford Street\, Burlington\, MA\, 01803\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200114T110000
DTEND;TZID=America/New_York:20200114T130000
DTSTAMP:20260501T074518
CREATED:20191209T225541Z
LAST-MODIFIED:20191209T225541Z
UID:7514-1578999600-1579006800@scienceinboston.com
SUMMARY:Exploring accessible R-groups using electrostatics and shape
DESCRIPTION:Overview\n\nSpark™ offers a rapid strategy for the identification of R-group replacements to explore new space. We will demonstrate in this hands-on workshop how Spark finds biologically equivalent replacements using electrostatic and shape character for key moieties in your molecule. Topics covered include R-group replacement\, grow a ligand into new space\, guided by existing ligands mapping a different region of the active site of your protein. \nHands-on: If you wish to follow along in this hands-on workshop then please bring a laptop (a download link to Spark will be provided before the event if needed). \nWho should attend: Medicinal\, synthetic and computational chemists with some experience of Spark.
URL:https://scienceinboston.com/event/exploring-accessible-r-groups-using-electrostatics-and-shape/
LOCATION:CIC\, Charles Room\, 14th Floor\, CIC\, 1 Broadway\, Cambridge\, MA\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200114T110000
DTEND;TZID=America/New_York:20200114T130000
DTSTAMP:20260501T074518
CREATED:20191209T225541Z
LAST-MODIFIED:20191209T225541Z
UID:27415-1578999600-1579006800@scienceinboston.com
SUMMARY:Exploring accessible R-groups using electrostatics and shape
DESCRIPTION:Overview\n\nSpark™ offers a rapid strategy for the identification of R-group replacements to explore new space. We will demonstrate in this hands-on workshop how Spark finds biologically equivalent replacements using electrostatic and shape character for key moieties in your molecule. Topics covered include R-group replacement\, grow a ligand into new space\, guided by existing ligands mapping a different region of the active site of your protein. \nHands-on: If you wish to follow along in this hands-on workshop then please bring a laptop (a download link to Spark will be provided before the event if needed). \nWho should attend: Medicinal\, synthetic and computational chemists with some experience of Spark.
URL:https://scienceinboston.com/event/exploring-accessible-r-groups-using-electrostatics-and-shape-2/
LOCATION:CIC\, Charles Room\, 14th Floor\, CIC\, 1 Broadway\, Cambridge\, MA\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200113T150000
DTEND;TZID=America/New_York:20200113T170000
DTSTAMP:20260501T074518
CREATED:20191209T224630Z
LAST-MODIFIED:20191209T224630Z
UID:7511-1578927600-1578934800@scienceinboston.com
SUMMARY:Beyond Bits to Bytes: Looking to the Future in Imaging and Data Science
DESCRIPTION:Overview\n\nThe role of data science in life science innovation is rapidly growing and evolving. If harnessed\, the information explosion has the potential to catalyze new discoveries and treatments in healthcare to benefit patients in need. During this time of digital transformation\, the potential exists to derive value from a wide variety of data sources\, including next generation sequencing\, mass spectrometry\, electronic health records\, images\, and consumer wearables. \nThe Massachusetts Life Sciences Center (MLSC) will convene various stakeholders to discuss how data is rapidly changing patient care. The gathering will feature voices from industry and academic research partners leading in this space. The event will feature a panel discussion covering a wide range of topics\, including requirements and standards for generating useful data\, patient privacy\, barriers to adoption\, and workforce training challenges. \nThe MLSC recently launched the second round of its Bits to Bytes Capital Call to provide funding for projects that will generate and analyze large datasets to answer pressing life science questions\, and train data scientists in the Commonwealth. The inaugural round of Bits to Bytes provided $6.7 million in capital funding to nine data-driven\, cross-sector projects focused on imaging\, cancer\, neuroscience\, drug discovery and clinical trial design.
URL:https://scienceinboston.com/event/beyond-bits-to-bytes-looking-to-the-future-in-imaging-and-data-science/
LOCATION:Broad Institute of MIT and Harvard\, 415 Main Street Auditorium\, Cambridge\, MA\, 02142\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200113T150000
DTEND;TZID=America/New_York:20200113T170000
DTSTAMP:20260501T074518
CREATED:20191209T224630Z
LAST-MODIFIED:20191209T224630Z
UID:27414-1578927600-1578934800@scienceinboston.com
SUMMARY:Beyond Bits to Bytes: Looking to the Future in Imaging and Data Science
DESCRIPTION:Overview\n\nThe role of data science in life science innovation is rapidly growing and evolving. If harnessed\, the information explosion has the potential to catalyze new discoveries and treatments in healthcare to benefit patients in need. During this time of digital transformation\, the potential exists to derive value from a wide variety of data sources\, including next generation sequencing\, mass spectrometry\, electronic health records\, images\, and consumer wearables. \nThe Massachusetts Life Sciences Center (MLSC) will convene various stakeholders to discuss how data is rapidly changing patient care. The gathering will feature voices from industry and academic research partners leading in this space. The event will feature a panel discussion covering a wide range of topics\, including requirements and standards for generating useful data\, patient privacy\, barriers to adoption\, and workforce training challenges. \nThe MLSC recently launched the second round of its Bits to Bytes Capital Call to provide funding for projects that will generate and analyze large datasets to answer pressing life science questions\, and train data scientists in the Commonwealth. The inaugural round of Bits to Bytes provided $6.7 million in capital funding to nine data-driven\, cross-sector projects focused on imaging\, cancer\, neuroscience\, drug discovery and clinical trial design.
URL:https://scienceinboston.com/event/beyond-bits-to-bytes-looking-to-the-future-in-imaging-and-data-science-2/
LOCATION:Broad Institute of MIT and Harvard\, 415 Main Street Auditorium\, Cambridge\, MA\, 02142\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200108T170000
DTEND;TZID=America/New_York:20200108T203000
DTSTAMP:20260501T074518
CREATED:20191209T224435Z
LAST-MODIFIED:20191209T224435Z
UID:7509-1578502800-1578515400@scienceinboston.com
SUMMARY:Post-Seed Venture Capital: What Is It? Is it Right for Me?
DESCRIPTION:Overview\n\nStartups: If you’re committed to your business vision\, then you MUST start planning for venture financing. \nEven if your startup is brand-new\, NOW is the time to map out your complete business growth path — all the way to venture financing. \nGet a crystal-clear picture of the process as we welcome three noted life science business financing experts to our Lowell center after work on Wednesday\, January 8. \nJoin us and: \n\nUnderstand how venture financing works today.\nLearn what to look for (and look OUT for) in a VC offer.\nLearn how to prepare your full business financing plan—from angel investors to VCs.\nFind out the preparations you need to make to advance to each stage of financing.\nGet expert answers to all your business financing questions.\nNetwork with VCs\, other investors\, and your entrepreneur peers.\nEnjoy complimentary snacks and beverages.\n\nPLUS\, practice and improve your pitch! \nCome with your pitch deck\, because you can enter your name to give your business presentation and get valuable feedback from our panel. \nAgenda: \n5:00 – Registration & Networking w/ food & drink \n5:30 – Fireside Chat with Bill Yelle\, Nancy Briefs\, and moderator Vinit Nijhawan. \n6:30 – Q&A and Networking \n  \nOnline tickets: $10.00 \nWalk-ins: $20.00 \n*This event will also include a 200k Challenge 2019 Info Session* \n*Free parking included*
URL:https://scienceinboston.com/event/post-seed-venture-capital-what-is-it-is-it-right-for-me/
LOCATION:M2D2\, 110 Canal Street\, 4th Floor\, Lowell\, MA\, 01854\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200108T170000
DTEND;TZID=America/New_York:20200108T203000
DTSTAMP:20260501T074518
CREATED:20191209T224435Z
LAST-MODIFIED:20191209T224435Z
UID:27413-1578502800-1578515400@scienceinboston.com
SUMMARY:Post-Seed Venture Capital: What Is It? Is it Right for Me?
DESCRIPTION:Overview\n\nStartups: If you’re committed to your business vision\, then you MUST start planning for venture financing. \nEven if your startup is brand-new\, NOW is the time to map out your complete business growth path — all the way to venture financing. \nGet a crystal-clear picture of the process as we welcome three noted life science business financing experts to our Lowell center after work on Wednesday\, January 8. \nJoin us and: \n\nUnderstand how venture financing works today.\nLearn what to look for (and look OUT for) in a VC offer.\nLearn how to prepare your full business financing plan—from angel investors to VCs.\nFind out the preparations you need to make to advance to each stage of financing.\nGet expert answers to all your business financing questions.\nNetwork with VCs\, other investors\, and your entrepreneur peers.\nEnjoy complimentary snacks and beverages.\n\nPLUS\, practice and improve your pitch! \nCome with your pitch deck\, because you can enter your name to give your business presentation and get valuable feedback from our panel. \nAgenda: \n5:00 – Registration & Networking w/ food & drink \n5:30 – Fireside Chat with Bill Yelle\, Nancy Briefs\, and moderator Vinit Nijhawan. \n6:30 – Q&A and Networking \n  \nOnline tickets: $10.00 \nWalk-ins: $20.00 \n*This event will also include a 200k Challenge 2019 Info Session* \n*Free parking included*
URL:https://scienceinboston.com/event/post-seed-venture-capital-what-is-it-is-it-right-for-me-2/
LOCATION:M2D2\, 110 Canal Street\, 4th Floor\, Lowell\, MA\, 01854\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200107T083000
DTEND;TZID=America/New_York:20200107T213000
DTSTAMP:20260501T074518
CREATED:20191209T224236Z
LAST-MODIFIED:20191209T224236Z
UID:7507-1578385800-1578432600@scienceinboston.com
SUMMARY:Harvard Medical School Master’s Degree Info Session
DESCRIPTION:Overview\n\nHarvard Medical School Postgraduate Medical Education Admissions team will host an online information session for three masters’ programs: Master in Clinical Service Operations\, Master of Healthcare Quality and Safety and Master of Medical Sciences in Clinical Investigation. \nHarvard Medical School faculty created these Master Degree Programs to address the needs of clinicians\, clinician-scientists and administrators in the areas of patient-oriented research\, and health care quality and safety. All three degrees combine innovative forms of pedagogy from leading Harvard faculty with an individual mentor experience in a Harvard affiliated laboratory or with a practical application at Harvard’s academic medical centers and community hospitals. \nAll degree programs prepare clinicians to assume leadership roles in their place of employment and to lead high profile projects.
URL:https://scienceinboston.com/event/harvard-medical-school-masters-degree-info-session/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200107T083000
DTEND;TZID=America/New_York:20200107T213000
DTSTAMP:20260501T074518
CREATED:20191209T224236Z
LAST-MODIFIED:20191209T224236Z
UID:27412-1578385800-1578432600@scienceinboston.com
SUMMARY:Harvard Medical School Master’s Degree Info Session
DESCRIPTION:Overview\n\nHarvard Medical School Postgraduate Medical Education Admissions team will host an online information session for three masters’ programs: Master in Clinical Service Operations\, Master of Healthcare Quality and Safety and Master of Medical Sciences in Clinical Investigation. \nHarvard Medical School faculty created these Master Degree Programs to address the needs of clinicians\, clinician-scientists and administrators in the areas of patient-oriented research\, and health care quality and safety. All three degrees combine innovative forms of pedagogy from leading Harvard faculty with an individual mentor experience in a Harvard affiliated laboratory or with a practical application at Harvard’s academic medical centers and community hospitals. \nAll degree programs prepare clinicians to assume leadership roles in their place of employment and to lead high profile projects.
URL:https://scienceinboston.com/event/harvard-medical-school-masters-degree-info-session-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191222T180000
DTEND;TZID=America/New_York:20191222T200000
DTSTAMP:20260501T074518
CREATED:20191209T231436Z
LAST-MODIFIED:20191209T231436Z
UID:7524-1577037600-1577044800@scienceinboston.com
SUMMARY:Going Beyond the Gut: The Future of Microbiome Therapeutics
DESCRIPTION:Overview\n\nThe microbiome market is one of the hottest areas for innovation in the life sciences space.  We are seeing an uptick in both research and venture capital dollars going into the microbiome industry—both in humans and plants.  As a result\, the global microbiome market is expected to grow from $235.8 million in 2018 to $521.23 million by 2022. \nPlease join us for a panel discussion led by some of Boston’s most innovative companies in the space to learn about the science behind the microbiome\, the utilization of emerging technologies\, and various perspectives on the future of the industry. \nConfirmed Speakers \nRyan Barrett\, VP\, Corporate Development & IP\,  Axial Biotherapeutics \nDr. Martha Herbert \, Assistant Professor of Neurology\, Harvard Medical School\, Pediatric Neurologist and Neuroscientist\,  Massachusetts General Hospital \nGeoff van Maltzahn\, Co-founder and Chief Innovation Officer\,  Indigo
URL:https://scienceinboston.com/event/going-beyond-the-gut-the-future-of-microbiome-therapeutics/
LOCATION:Broad Institute of MIT and Harvard\, 415 Main Street Auditorium\, Cambridge\, MA\, 02142\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191222T180000
DTEND;TZID=America/New_York:20191222T200000
DTSTAMP:20260501T074518
CREATED:20191209T231436Z
LAST-MODIFIED:20191209T231436Z
UID:27419-1577037600-1577044800@scienceinboston.com
SUMMARY:Going Beyond the Gut: The Future of Microbiome Therapeutics
DESCRIPTION:Overview\n\nThe microbiome market is one of the hottest areas for innovation in the life sciences space.  We are seeing an uptick in both research and venture capital dollars going into the microbiome industry—both in humans and plants.  As a result\, the global microbiome market is expected to grow from $235.8 million in 2018 to $521.23 million by 2022. \nPlease join us for a panel discussion led by some of Boston’s most innovative companies in the space to learn about the science behind the microbiome\, the utilization of emerging technologies\, and various perspectives on the future of the industry. \nConfirmed Speakers \nRyan Barrett\, VP\, Corporate Development & IP\,  Axial Biotherapeutics \nDr. Martha Herbert \, Assistant Professor of Neurology\, Harvard Medical School\, Pediatric Neurologist and Neuroscientist\,  Massachusetts General Hospital \nGeoff van Maltzahn\, Co-founder and Chief Innovation Officer\,  Indigo
URL:https://scienceinboston.com/event/going-beyond-the-gut-the-future-of-microbiome-therapeutics-3/
LOCATION:Broad Institute of MIT and Harvard\, 415 Main Street Auditorium\, Cambridge\, MA\, 02142\, United States
END:VEVENT
END:VCALENDAR